ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 604,45
1,14%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Monopar Therapeutics Inc (MNPR)

  7. Monopar Therapeutics Inc (MNPR) Actualités

MNPR Monopar Therapeutics Inc

0,734
0,074 (11,21%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Monopar Therapeutics Inc MNPR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,074 11,21% 0,734 01:11:34
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,67 0,6433 0,7624 0,7272 0,66
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202414:00GLOBEMonopar Announces Radiopharma Presentation Selected for..
16/4/202414:00GLOBEMonopar Announces Filing of Patent Protecting MNPR-101..
10/4/202414:00GLOBEMonopar Initiates Radiopharma Phase 1 Clinical Trial for..
28/3/202412:00GLOBEMonopar Reports Fourth Quarter and Full-Year 2023 Financial..
07/3/202414:30EDGAR2Form 8-K - Current report
05/3/202413:00EDGAR2Form 8-K - Current report
05/3/202413:00GLOBEMonopar Announces Positive Preclinical Therapeutic Isotope..
28/2/202419:45EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical..
27/2/202412:59EDGAR2Form 8-K - Current report
22/2/202413:00EDGAR2Form 8-K - Current report
22/2/202413:00GLOBEMonopar Announces Promising Preclinical Data for its..
20/2/202414:00EDGAR2Form 8-K - Current report
20/2/202414:00GLOBEMonopar Receives Clearance to Proceed with First-in-Human..
04/1/202401:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:00EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEMonopar Therapeutics Reports Third Quarter 2023 Financial..
01/11/202312:00EDGAR2Form 8-K - Current report
01/11/202312:00GLOBEMonopar Presents Data Showing Tumor Reduction Benefit of..
10/10/202313:00GLOBEMonopar to Participate in the Roth MKM 2023 Healthcare..
04/10/202301:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202301:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202313:00GLOBEMonopar to Participate in the H.C. Wainwright 25th Annual..
30/8/202323:16EDGAR2Form 8-K - Current report
10/8/202313:00EDGAR2Form 8-K - Current report
10/8/202313:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:00GLOBEMonopar Therapeutics Reports Second Quarter 2023 Financial..
08/8/202313:00EDGAR2Form 8-K - Current report
08/8/202313:00GLOBEMonopar Provides Encouraging Camsirubicin Clinical Data..
11/7/202313:00EDGAR2Form 8-K - Current report
11/7/202313:00GLOBEMonopar Announces MNPR-101 Radiopharma Collaboration..
04/7/202300:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/7/202300:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202322:13EDGAR2Form 8-K - Current report
21/6/202313:00GLOBEMonopar to Participate in the Radiopharma Forum by the Lake..
14/6/202313:00GLOBEMonopar to Participate in the Maxim Group’s Healthcare..
01/6/202313:00GLOBEMonopar Announces Encouraging Camsirubicin Phase 1b Trial..
11/5/202313:00GLOBEMonopar Therapeutics Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
MNPR
Monopar Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés